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The prognosis of autosomal recessive polycystic kidney
disease is known to correlate with genotype. The presence of
two truncating mutations in the PKHD1 gene encoding the
fibrocystin protein is associated with neonatal death while
patients who survive have at least one missense mutation.
To determine relationships between genotype and renal and
hepatic abnormalities we correlated the severity of renal and
hepatic histological lesions to the type of PKHD1mutations in
54 fetuses (medical pregnancy termination) and 20 neonates
who died shortly after birth. Within this cohort, 55.5% of the
mutations truncated fibrocystin. The severity of cortical
collecting duct dilatations, cortical tubule and glomerular
lesions, and renal cortical and hepatic portal fibrosis
increased with gestational age. Severe genotypes, defined by
two truncating mutations, were more frequent in patients of
less than 30 weeks gestation compared to older fetuses and
neonates. When adjusted to gestational age, the extension of
collecting duct dilatation into the cortex and cortical tubule
lesions, but not portal fibrosis, was more prevalent in
patients with severe than in those with a non-severe
genotype. Our results show the presence of two truncating
mutations of the PKHD1 gene is associated with the most
severe renal forms of prenatally detected autosomal
recessive polycystic kidney disease. Their absence, however,
does not guarantee survival to the neonatal period.
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Autosomal recessive polycystic kidney disease (ARPKD) is
characterized by the association of bilateral renal cystic
disease and congenital hepatic fibrosis (CHF). ARPKD can
involve a wide spectrum of clinical phenotypes, correlated in
part with the age at presentation.1,2 The most severe forms of
the disease, accounting for about 40% of cases, are detected
early during gestation by ultrasonography that shows
tremendously enlarged echogenic kidneys and oligohydram-
nios. If medical pregnancy termination is not performed,
most of these infants die in the perinatal period from
respiratory insufficiency due to pulmonary hypoplasia. But
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over half of the patients are detected late during pregnancy or
are undetected prenataly and survive the perinatal period.
More than half of them require kidney transplantation before
reaching 20 years of age, whereas others have preserved renal
function until adulthood.1–5 CHF complications such as
bleeding esophageal varices and cholangitis, may occur as
soon as early childhood or during adulthood, sometimes
years after renal transplantation.6
ARPKD is caused by mutations in the PKHD1 gene that
encodes the protein fibrocystin expressed in the primary cilia
and the basal body of renal and bile ducts epithelial cells.7–14
Presently, 303 mutations of PKHD1 have been reported in
ARPKD patients (http://www.humgen.rwth-aachen.de/).
Several studies have shown that truncating mutations were
present in about 55% of the most severe cases—medical
pregnancy termination or early demise patients—but only in
about 20% of live patients.10,15–22 But no study ever analyzed
the relationship between the severity of histological renal and
hepatic lesions and the genotype.
The aim of our study was to investigate the genotype–-
phenotype correlations in a cohort of 74 fetuses or early
demise patients with ARPKD, by analyzing the relations
between the histological severity of renal and hepatic lesions
and the type of PKHD1 mutations.
RESULTS
Renal and hepatic histology
According to inclusion criteria, dilatation of medullar
collecting ducts, radially oriented, was present in the 73
available kidney specimens. Portal fibrosis and increased
number and dilatation of bile ducts were present in the 61
available liver specimens.
The severity of renal lesions was evaluated according to
five criteria: (i) The extension in the cortex of the dilatation
of collecting ducts, which was graded as either absent, or
partial if present only in the inner part of the cortex, with
preservation of the nephronic zone and the superficial rows
of developing nephrons, or global if affecting the whole
cortex up to the subcapsular areas (Figure 1). (ii) The
presence of degenerative changes of cortical tubules (prox-
imal and distal convoluted tubules) that may be dediffer-
entiated, atrophic or reduced in number. According to their
extension and severity, lesions were classified as grade 1:
absent of significant changes or mild tubular lesions mostly
seen in the deep cortex; grade 2: moderate but diffuse tubular
lesions; grade 3: massive reduction in the number of
nephrons with complete disappearance of proximal tubules
(Figure 2a to f). (iii) The absence or presence of proximal
tubule dilatation with preservation of a normal epithelium
(Figure 2g). (iv) The appearance of the glomeruli: they may
be normal or present unspecific changes within interstitial
fibrotic areas, from retraction to collapse, often surrounded
by a thickened Bowman’s capsule. The lesions were classified
as absent, partial or global (Figure 2a to h). (v) The change in
the cortical interstitium: fibrosis or fibro-oedema was either
absent, focal, or diffuse (Figure 2i).
In the liver, the severity of lesions was categorized according
to the importance of portal fibrosis, classified as grade 1:
presence of mild fibrosis, only touching the largest portal
tracts; grade 2: fibrosis of all portal tracts, whatever their size;
grade 3: massive fibrosis leading to marked enlargement of all
portal tracts with fibrous extensions bridging adjacent portal
areas (Figure 3).
Extension of collecting duct dilatation in the cortex was
absent in three cases (4%), partial in 35 cases (48%) and
global in 35 cases (48%). Cortical tubule lesions were grade 1
in 19 cases (26%), grade 2 in 29 cases (40%), and grade 3 in
25 cases (34%). Proximal tubule dilatation was observed in
26 cases (37%). Glomerular lesions were present in 44 cases
(62%) and cortical fibrosis in 24 cases (34%) (Table 1 and
Supplementary Table S1). Portal fibrosis was grade 1 in
5 cases (8%), grade 2 in 41 cases (67%), and grade 3 in 15
cases (25%) (Table 1 and Supplementary Table S1).
The degree of extension of collecting duct dilatation within
the cortex was significantly correlated with the severity of
cortical tubule lesions, glomerular lesions and cortical fibrosis.
Proximal tubule dilatation was the only lesion that was
significantly more frequent when collecting duct dilatation in
the cortex was absent or partial compared with global
(Table 2). There was also a correlation, close to significance,
between the extension of collecting duct dilatation within the
cortex and the grade of portal fibrosis (Table 2).
The degree of extension of collecting duct dilatation
within the cortex, the severity of cortical tubule and
glomerular lesions significantly increased with gestational
age (GA). A similar trend was observed between the severity
of cortical fibrosis and GA. Proximal tubule dilatation was
the only lesion that was significantly more frequent when GA
was p30 weeks compared with 430 weeks. The grade of
portal fibrosis also significantly increased with GA (Table 1).
Absent Partial
Global
Figure 1 |Categorization of the extension in the renal cortex
of the collecting duct dilatation. (a) Absent (patient 48);
(b) partial (patient 6); (c) global (patient 49). Histological sagittal
sections of fetal kidneys. Hematoxylin and eosin safran staining.
Bar¼ 1mm. For information on patients, see Supplementary
Table S1.
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The impact of GA on histological lesions is illustrated in
Figure 4, showing renal and hepatic lesions in two
consecutive affected foetuses of the same family (patient
54), at 27 weeks and 13 weeks of GA, respectively.
PKHD1 mutations
A total of 128 mutations were detected, four patients (no. 17,
36, 59, and 60) had three mutations (Supplementary Table S2).
The detection rate of the mutations was 83.8% (124 mutated
alleles out of 148 expected). Among the 75 distinct identified
mutations (Supplementary Table S3), 41 (54.6%) were not
previously reported according to the PKHD1 mutation
database (http://www.humgen.rwth-aachen.de/). At least two
mutations were detected in 53 patients (71.6%) and one
mutation in 18 patients (24.3%). No mutations could be
detected in three patients.
a
Grade 1 Grade 2 Grade 3
b c
d e f
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Figure 2 |Categorization of cortical lesions. (a–f) Grading of cortical tubule lesions with (a, d): grade 1 (patient 68), despite some degree
of autolysis, tubule morphology is preserved; (b, e): grade 2 (patient 6), epithelial dedifferentiation and atrophy of some cortical tubules
leading to irregular dilatation; (c, f ): grade 3 (patients 70 and 12), cortical tubules are scanty and dedifferentiated. (g) dilatation of proximal
tubules without epithelial lesions (patient 72). (a, b, d–h) grading of glomerular lesions with (a, b, d, e): normal glomeruli (patients 68 and 6);
(g) modest retraction of the glomeruli (patient 72); (f, h) moderate to complete retraction of the glomeruli (patient 12). (i) focal cortical
interstitial fibrosis (patient 15). Histological sagittal sections of kidneys. Hematoxylin and eosin safran staining. Bar—a, b, c¼ 300 mm;
d, e, f, g, i¼ 80mm, h¼ 150mm. *Proximal convoluted tubule; 1distal convoluted tubule. For information on patients, see Supplementary
Table S1.
352 Kidney International (2010) 77, 350–358
or ig ina l a r t i c l e E Denamur et al.: Renal/hepatic histology and PKHD1 mutations
Seventy-one mutations (55.5%) were truncating with 44
frameshifting small deletions/insertions/duplications, 24
nonsense mutations and three splice mutations with exon
skipping, leading to out of frame fusion of exons. Fifty-four
mutations (42.2%) were missense mutations. One mutation
was a missense mutation associated with an in-frame
insertion of six bases in exon 16, one mutation was an in-
frame deletion of 42 bases in exon 30 and one mutation was a
one-base deletion in exon 67 leading to the change of the last
12 amino acids of the fibrocystin, the abolition of the stop
codon and the addition of nine amino acids (Supplementary
Tables S2 and S3). Parent DNA analysis in the four patients
with three mutations showed that the co-inherited mutations
were always missense mutations (Supplementary Table S2).
We observed eight patients with homozygous mutations,
implicating truncating mutations in all except one (Supple-
mentary Table S2). When parents DNAs were available (five
cases), the homozygous character of the mutation was
confirmed by testing both parents. In the three remaining
cases, intragenic SNPs and intra and flanking extragenic
microsatellites showed a homozygous pattern (data not
shown), indicating that the mutation was either homozygous,
or in combination with a large PKHD1 deletion.
Mutations were observed all along the gene, scattered in 41
exons. However, three mutations were recurrent: the T36M
missense (n¼ 13) in exon 3 and the frameshifts c.5895dupA
(L1966fs) (n¼ 9) in exon 36 and c.9689delA (D3230fs)
(n¼ 13) in exon 58 (Supplementary Tables S2 and S3).
Furthermore, the screening of 6 exons (3, 32, 36, 57, 58, and
61) allowed the identification of 51% of mutations.
Grade 1 Grade 2
Grade 3
Figure 3 |Categorization of portal fibrosis severity. (a) Grade 1
(patient 25); (b) grade 2 (patient 6); (c) grade 3 (patient 33).
Histological sections of livers. Trichrome staining. Bar¼ 1mm. For
information on patients, see Supplementary Table S1.
Table 1 | Relationships between gestational age and severity
of renal and hepatic lesions
N GA p30 weeks GA 430 weeks P-value
Renal lesions
Collecting duct
dilatation in
the cortex
73 o103
Absent 2 (6) 1 (3)
Partial 26 (72) 9 (24)
Global 8 (22) 27 (73)
Cortical tubule lesions 73 0.02
Grade 1 13 (36) 6 (16)
Grade 2 16 (44) 13 (35)
Grade 3 7 (19) 18 (49)
Proximal tubule
dilatation
71 o103
No 16 (44) 29 (83)
Yes 20 (56) 6 (17)
Glomerular lesions 71 o103
Absent 20 (56) 7 (20)
Partial 11 (31) 9 (26)
Global 5 (14) 19 (54)
Cortical fibrosis 71 0.08
Absent 28 (78) 19 (54)
Focal 6 (17) 9 (26)
Diffuse 2 (6) 7 (20)
Portal fibrosis 61 0.002
Grade 1 3 (12) 2 (6)
Grade 2 22 (84) 19 (54)
Grade 3 1 (4) 14 (40)
Abbreviation: GA, gestational age.
Results are expressed as numbers (percentages).
For definition of lesions: see Results, Renal and hepatic histology.
Table 2 | Relationships between the degree of extension of
collecting duct dilatation in the cortex and the severity of
cortical tubule lesions, proximal tubule dilatation, glomerular
lesions, cortical fibrosis and portal fibrosis
Collecting ducts dilatation
in the cortex N Absent Partial Global P-value
Cortical tubule lesions 73 o103
Grade 1 3 (100) 16 (46) 0
Grade 2 0 18 (51) 11 (31)
Grade 3 0 1 (3) 24 (69)
Proximal tubule dilatation 71 o103
No 0 14 (41) 31 (91)
Yes 3 (100) 20 (59) 3 (9)
Glomerular lesions 71 o103
Absent 3 (100) 23 (68) 1 (3)
Partial 0 11 (32) 9 (26)
Global 0 0 24 (71)
Cortical fibrosis 71 o103
Absent 3 (100) 30 (88) 14 (41)
Focal 0 4 (12) 11 (32)
Diffuse 0 0 9 (26)
Portal fibrosis 60 0.09
Grade 1 1 (50) 2 (7) 2 (7)
Grade 2 1 (50) 22 (79) 17 (57)
Grade 3 0 4 (14) 11 (37)
Results are expressed as numbers (percentages).
For definition of lesions: see Results, Renal and hepatic histology.
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Additional 6 exons (9, 14, 18, 19, 22, and 34) led to a
detection rate of 64%.
Genotype–phenotype correlation analysis
For this analysis, truncating mutations (T) (nonsense,
frameshift and splice mutations) and non-truncating muta-
tions (NT) (missense mutations and diverse in-frame
modifications) were considered (Supplementary Table S2).
According to the fact that the disease is recessive with a loss of
function of the fibrocystin protein, we considered genotype
as severe when two truncating mutations were present (T/T,
21 patients) and non-severe if at least one NT mutation was
present (41 patients including 20 with NT/T, 12 with NT/NT
and 9 with NT/non identified (NI) mutations). Patients with
T/NI (nine patients) or NI/NI (three patients) mutations
were excluded for the genotype–phenotype correlation
analysis as they could have undetected severe mutations
such as an intragenic or large PKHD1 deletion, not screened
in our study.
Severe genotype was significantly more frequent in fetuses
that underwent medical pregnancy termination at 30 weeks
of GA or less (53%) compared to those with GA over
30 weeks (16%, including three medical pregnancy termina-
tions and two post-natal deaths). Conversely, the majority of
patients who underwent medical pregnancy termination after
30 weeks of GA or who died after birth had non-severe
genotype (Table 3). It is interesting to note that 10 different
missense mutations (T36M, I222V, R328G, T1300K, C1692Y,
P1791L, R2370G, W2736G, I2957T, and R3240K) were
identified among the 16 patients with non-severe genotype
who died after birth.
When GA was not taken into account, no correlation was
found between the severity of genotype and any of the
histological criteria of severity (Supplementary Table S4).
However, when adjusted to GA, the degree of extension of
collecting duct dilatation in the cortex was significantly more
important in the patients with severe genotype compared to
those with non-severe genotype. The grade of cortical tubule
lesions adjusted to GA was also more important in the
patients with severe genotype than in those with non-severe
genotype (Table 4). Proximal tubule dilatation, glomerular
lesions, cortical fibrosis, and hepatic fibrosis adjusted on GA
were not significantly different between the two groups of
genotype (Table 4).
DISCUSSION
This is the first series of ARPKD patients who analyzed the
genotype–phenotype correlations via the relations between
the severity of renal and hepatic histological lesions and
PKHD1 mutations.
The severity of the disease in this series of prenatally
detected ARPKD was confirmed by the association of severe
cortical lesions with the typical dilatation of collecting ducts
in the medulla. Extension to the cortex of collecting duct
dilatation was observed in 96% of patients and cortical tubule
lesions grade 2 or 3 in 74% of the patients. Similarly, portal
fibrosis grade 2 or 3 was present in 92% of patients (Table 1
and Supplementary Table S1). It is generally considered that
cortical lesions in ARPKD are the consequence of compres-
sion by the cystic collecting ducts extending to the cortex.
Our series confirms that the severity of cortical tubule
lesions, glomerular lesions, and cortical fibrosis were
significantly correlated with the degree of extension of
a b
dc
Figure 4 |Correlation of renal and hepatic lesions with
gestational age (GA): example from two siblings with
different GA. (a) Histological sagittal section of the kidney of
patient 54 (27 weeks of GA), showing extensive dilatation of
collecting ducts, and moderate lesions of cortical tubules (grade
2). (b) Histological sagittal section of the kidney of the sibling of
patient 54, at 13 weeks of GA; the dilatation of collecting ducts is
mainly seen in the medulla; the nephrons are preserved apart
from some proximal and distal tubule dilatation. *Proximal
convoluted tubule; 1distal convoluted tubule. (c) Histological
aspect of the liver in patient 54, showing numerous dilated bile
ducts, enlarged portal tracts and grade 2 portal fibrosis. (d)
Histological aspect of the liver of sibling at 13 weeks of GA
showing very mild dilatation of bile ducts and slight enlargement
of portal tract. (a,b,d) hematoxylin and eosin safran staining; (c)
trichrome staining. Bar—a¼ 300mm; b, d¼ 150mm; c¼ 1mm.
Table 3 | Distribution of gestational age at medical pregnancy
termination or death according to genotype (severe or
non-severe)
Genotype
N Non-severe Severe
62 N=41 N=21 P-value
Medical pregnancy termination
p30 weeks
30 14 16 (53) 0.006
Medical pregnancy termination
430 weeks
14 11 3 (21)
Post-natal demise 18 16 2 (11)
Results are expressed as numbers (percentages per row).
For definition of genotypes: see Results, Genotype–phenotype correlation analysis.
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collecting duct dilatation within the cortex (Table 2). It is
interesting to note that a correlation close to significance was
also found between the degree of portal fibrosis and the
extension of collecting ducts in the renal cortex, suggesting
that renal and hepatic involvement have a parallel severity in
the most severe forms of ARPKD detected prenatally.
A prerequisite before investigating the correlations
between histological phenotype and genotype was to analyze
the effect of GA on the severity of histological lesions. Our
study confirmed that the degree of extension of collecting
duct dilatation within the renal cortex, the severity of cortical
tubule lesions, glomerular lesions, cortical fibrosis, and portal
fibrosis increased significantly with GA (Table 1), a logical
issue, but not demonstrated previously in humans, even in
the seminal studies of Osathanonah and Potter.23 The only
histological abnormality, which we observed to be more
frequent when GA was p30 weeks compared with 430
weeks was the dilatation of proximal tubules (Table 1), which
also was more frequent when the extension of collecting duct
dilatation within the cortex was absent or partial compared
with global (Table 2). Dilatation of proximal tubules has been
reported as an early lesion, preceding collecting duct cystic
dilatation in human ARPKD fetuses24 and several mouse
models of ARPKD.25–29 Ward et al.9 have shown that the
PKHD1 protein fibrocystin is expressed in embryonic human
kidneys not only in the branching ureteric ducts and
collecting ducts, but also, with a weaker intensity, in the
developing nephrons. In addition, expression of fibrocystin
has been shown in human adult12 and in mouse30 proximal
tubules.
In this series of severe ARPKD, the mutation detection
rate was 83.8%, a proportion similar to that reported in series
including the most severe forms of the disease.10,15–18 Two
mutations were identified in 71.6% of patients, one in 24.3%,
and none in three patients (2.4%). This repartition is similar
to that reported by Bergmann et al.16 in families requesting
prenatal diagnosis after having lost a child with severe
ARPKD. Among the 75 different mutations, 41 (54.6%) were
unreported, expending the spectrum of known PKHD1
mutations from 303 to 344. We found that the proportion
of truncating mutations was around 55%, exactly as in series
of patients with early demise, compared with 21–23% in
series of living patients.10,15–17,20,21 Most patients with 2
truncating mutations die in the neonatal period.10,15,17
Overall, at least one amino acid substitution mutation is
necessary for survival in the neonatal period.21 In our series,
severe genotypes, characterized by two truncating mutations,
predominated in the forms of ARPKD detected relatively
early by prenatal ultrasonography. However, the 16 neonates
with non-severe genotype died shortly after birth, indicating
that the absence of two truncating mutations cannot be
regarded as synonymous of a favorable prognosis (Table 3).
Considering that most histological lesions increased with
GA, it is not surprising that the intrinsic effect of mutations
on histological lesions could not be evidenced when GA was
not taken into account. On the other hand, after adjustment
Table 4 | Relationships between genotype (severe or
non-severe) and renal lesions and portal fibrosis adjusted to
gestational age
Genotype
N Non-severe Severe P-value
Renal lesions
Collecting duct dilatation
in the cortex
61 0.01
GA p30 weeks
Absent or partial 25 14 11 (44)
Global 5 0 5 (100)
GA 430 weeks
Absent or partial 7 7 0
Global 24 20 4 (17)
Cortical tubule lesions 61 0.07
GA p30 weeks
Grade 1 11 4 7 (64)
Grade 2 15 10 5 (33)
Grade 3 4 0 4 (100)
GA 430 weeks
Grade 1 3 3 0
Grade 2 11 10 1 (9)
Grade 3 17 14 3 (18)
Proximal tubule dilatation 59 0.44
GA p30 weeks
No 12 5 7 (58)
Yes 18 9 9 (50)
GA 430 weeks
No 25 21 4 (16)
Yes 4 4 0
Glomerular lesions 59 0.34
GA p30 weeks
Absent 17 9 8 (47)
Partial 11 5 6 (55)
Global 2 0 2 (100)
GA 430 weeks
Absent 3 3 0
Partial 8 7 1 (13)
Global 18 15 3 (17)
Cortical fibrosis 59 0.85
GA p30 weeks
Absent 24 11 13 (54)
Focal 5 3 2 (40)
Diffuse 1 0 1 (100)
GA 430 weeks
Absent 13 12 1 (8)
Focal 9 7 2 (22)
Diffuse 7 6 1 (14)
Portal fibrosis 52 0.69
GA p30 weeks
Grade 1 3 2 1 (33)
Grade 2 19 10 9 (47)
Grade 3 1 1 0
GA 430 weeks
Grade 1 2 2 0
Grade 2 15 12 3 (20)
Grade 3 12 10 2 (17)
For definition of lesions: see Results, Renal and hepatic histology.
For definition of genotypes: see Results, Genotype–phenotype correlation analysis.
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of histological lesions to GA, severe genotype was correlated
with significantly more severe extension of collecting duct
dilatation in the cortex and to a lesser degree, to more severe
lesions of cortical tubules than non-severe genotype (Table 4).
However, the degree of proximal tubule dilatation, glomer-
ular lesions, and cortical fibrosis, as well as the severity of
portal fibrosis, adjusted to GA, were not significantly
different according to the severity of the genotype (Table 4).
Although the cohort of patients was relatively important, it
probably was insufficient for these criteria to reach statistical
significance.
Additional events may interfere with the genotype–phe-
notype correlations. First, as allelic variation in gene
expression is common in the human genome,31 this can
modulate the level of the various PKHD1 mutants, leading to
differences in phenotypic expression. Second, modifier genes
could also modulate the phenotype despite a unique PKHD1
genotype.32 Interactions between PKHD1 and HNF1B,33 the
kinesin family member 12,34 or PKD135 and PKD2,36,37 the
mouse orthologs of the genes linked to human autosomal
dominant polycystic kidney disease, have been shown in
animal models.
In conclusion, this study shows that the presence of two
truncating mutations in PKHD1 is associated with the most
severe renal lesions in patients with ARPKD detected early
during pregnancy. However, patients with late prenatal
detection, less severe histological lesions and without two
truncating mutations may have postnatal demise, showing
the limits of genetic screening to predict the clinical outcome.
MATERIALS AND METHODS
Criteria for the inclusion in the study
Histological confirmation of the diagnosis of ARPKD/CHF was
the prerequisite for inclusion. Histological criteria for ARPKD were:
(i) fusiform dilatation of the collecting ducts, with a radial
disposition from the calyx and medulla towards the cortex38–40 (ii)
CHF defined by portal fibrosis surrounding increased numbers of
hyperplasic and ectatic biliary ducts, with normal hepatocellular
histology.39,40 In a single patient without renal histology, the
diagnosis of ARPKD relied on liver histology and the presence of
PKHD1 mutations.
Patients
Patients were recruited by three French laboratories involved in the
genetic diagnosis of ARPKD (Department of Genetics, Pr A.
Munnich, Hoˆpital Necker-Enfants Malades, Paris and the labora-
tories of ED and L M-C).
Seventy-four patients representing 74 unrelated nuclear families
were studied, including 54 fetuses (median GA at medical pregnancy
termination: 28 weeks (14–37 weeks)), and 20 postnatal demise
patients (median age at death, 20 days (1 day to 6 months)). Median
GA for the whole cohort was 30 weeks. In the case of kindred
(12 siblings, six pedigrees) or twins (four twins, two pedigrees), only
the first propositus was included in the study because the
comparison of histological data in the siblings of similar GA or
twins did not indicate intrafamilial variability.
Father and mother’s country of birth was France in 70 and 77%
of cases, respectively. Other parents were of Italian (4%), Turkish
(4%), Spanish (2%), Finish (1%), Algerian (1%), Lebanon (1%) or
Chinese (1%) origin. Origin was unknown in 15% of parents.
Histological study
Renal specimens were available in 73 cases and liver specimens in 61,
including the only patient with no renal tissue available. All
specimens were collected during autopsy except one (post-mortem
biopsy). They were fixed in 4% buffered formalin and embedded in
paraffin. Special attention was paid for taking frontal cortico-
medullary sections of the kidney passing through the hilus allowing
correct analysis of cystic structures. Five micrometer-thick sections
were stained with trichrome, hematoxylin eosin safran or periodic
acid of Schiff. Some of the samples were examined after Red Sirius
staining of fibrosis, or after immunohistochemical-specific identi-
fication of collecting ducts (using anti-EMA antibody) or proximal
tubules (using CD15 antibody). They were examined independently
by three pathologists (ALD, MCG, and RB) for confirmation of the
diagnosis and evaluation of the severity of kidney and liver lesions.
The evaluation was concordant between the 3 pathologists in all
cases except 4, leading to common re-examination of the slides of
these patients.
PKHD1 mutation screening
For each patient, informed consent for genetic testing was obtained
from both parents. Genomic DNA was isolated from the index cases
using standard procedures on the following samples: amniotic fluid,
chorionic villus, lung or liver tissue obtained during the autopsy,
peripheral blood. GenomiPhi HY DNA amplification kit (GE
Healthcare Europe GmbH, Orsay, France) was then used for the
representational amplification of the extracted DNA as a limited
amount of DNA was obtained from the original samples. Mutation
screening was done for the 66 exons encoding the 4074 amino acids
fibrocystin protein, including splice sites and at least 20 bp of
intronic sequence. Preamplified DNA was subjected to PCR using
the primer sets described in Supplementary Table S5, thus
generating 66 PCR fragments of 198 to 1840 bp for direct
sequencing. PCR amplification was performed using Thermo-Start
DNA Polymerase Mastermix from Abgene (Epsom, UK) on 30 to
60 ng of genomic DNA according to the manufacturer’s recommen-
dations. The cycling conditions were as follows: 1 15min 95 1C;
35 30 s 95 1C, 30 s 55 1C, 2min 72 1C; 1 5min 72 1C. Direct
sequencing was performed on both strands using the reverse and
forward primers designed for amplification and the BigDye
terminator chemistry on ABI 3730XL capillary sequencers (Applied
Biosystems, Foster City, CA, USA). Additional sequencing internal
primers were used for exons 32, 58, and 61 (Supplementary
Table S5).
PKHD1 sequence analysis
Sequence alignments were done using Seqscape software (Applied
Biosystems). Classification of the DNA variations was done
according to the Mutation Database for ARPKD from the Aachen
University (http://www.humgen.rwth-aachen.de).
Newly described variations were classified as polymorphism or
mutation as follows. Silent sequence variations (intronic or exonic)
were classified as polymorphism. Truncating mutations (nonsense
mutations, non in-frame insertions and deletions and consensus
splice mutations (Supplementary Table S6)) were classified as
deleterious mutations. Finally, missense mutations were analyzed
using six different tests: conservation between human, chimpanzee, dog,
mouse, chicken, and frog PKHD1 protein19 and five in silico protein
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structure and function prediction programs (Supplementary Table
S7). Sequence variation was considered as causing disease mutation
when at least 50% of the performed tests predicted a pathological
effect. Of the 13 unreported missense mutations, all but one
(S1867G) fulfilled those criteria. However, as the S1867 is
evolutionary conserved and the S1867N variation was reported as
deleterious in a previous mutation study (http://www.humgen.rwth-
aachen.de), we considered S1867G as a missense mutation
(Supplementary Table S7).
Statistical analysis
Results were expressed as median (range) for quantitative variables
and numbers (percentages) for categorical variables. Associations
between categorical variables were examined with w2, Fischer’s exact
test or trend w2 statistics as appropriate. The study of relationships
between severity of mutations and renal/hepatic lesion grades were
adjusted on gestational age dichotomized at median value using
Cochran–Mantel–Haenszel statistics. All tests were two-sided and
values ofo0.05 were considered statistically significant. All analyses
were performed with SAS statistical package (SAS 9.1, SAS Inc.,
Cary, NC, USA).
DISCLOSURE
All the authors declared no competing interests.
ACKNOWLEDGMENTS
We thank ML Gaume (CHU Montpellier), M Peuchmaur (Hoˆpital
Robert Debre´, Paris), J Politis (CH Vannes), H Sevestre (CHU Amiens)
and S Vanecloo (CH Valenciennes) for providing tissue specimens and
C Antignac and A Munnich for providing some of the DNAs studied in
this work. We are grateful to the anonymous reviewers for their
careful and constructive suggestions. This work has been partially
reported during the 40th Annual Meeting of the European Society of
Paediatric Nephrology, Palermo, Italy, 7 October 2006. Supported by
the Programme Hospitalier de Recherche Clinique (AOM 03 024),
De´le´gation a` la Recherche Clinique–Ile de France, Assistance
Publique-Hoˆpitaux de Paris and the Association pour l’Information et
la Recherche sur les Maladies Re´nales Ge´ne´tiques.
SUPPLEMENTARY MATERIAL
Table S1. Clinical and histological data.
Table S2. Mutations in PKHD1 and corresponding genotype.
Table S3. Distinct mutations in PKHD1.
Table S4. Relationships between genotype, renal lesions and portal
fibrosis non-adjusted to gestational age.
Table S5. Primers for PCR amplification and sequencing of PKHD1
Table S6. Characteristics of splice mutations.
Table S7. Characteristics of missense mutations.
Supplementary material is linked to the online version of the paper at
http://www.nature.com/ki
REFERENCES
1. Zerres K, Mucher G, Becker J et al. Prenatal diagnosis of autosomal
recessive polycystic kidney disease (ARPKD): molecular genetics,
clinical experience, and fetal morphology. Am J Med Genet 1998; 76:
137–144.
2. Guay-Woodford LM, Desmond RA. Autosomal recessive polycystic kidney
disease: the clinical experience in North America. Pediatrics 2003; 111:
1072–1080.
3. Zerres K, Rudnik-Schoneborn S, Deget F et al. Autosomal recessive
polycystic kidney disease in 115 children: clinical presentation, course
and influence of gender. Acta Paediatr 1996; 85: 437–445.
4. Roy S, Dillon MJ, Trompeter RS et al. Autosomal recessive polycystic
kidney disease: long-term outcome of neonatal survivors. Pediatr Nephrol
1997; 11: 302–306.
5. Capisonda R, Phan V, Traubuci J et al. Autosomal recessive polycystic
kidney disease: outcomes from a single-center experience. Pediatr
Nephrol 2003; 18: 119–126.
6. Shneider BL, Magid MS. Liver disease in autosomal recessive polycystic
kidney disease. Pediatr Transplant 2005; 9: 634–639.
7. Onuchic LF, Furu L, Nagasawa Y et al. PKHD1, the polycystic kidney and
hepatic disease 1 gene, encodes a novel large protein containing
multiple immunoglobulin-like plexin-transcription-factor domains
and parallel beta-helix 1 repeats. Am J Hum Genet 2002; 70:
1305–1317.
8. Ward CJ, Hogan MC, Rossetti S et al. The gene mutated in autosomal
recessive polycystic kidney disease encodes a large, receptor-like protein.
Nat Genet 2002; 30: 259–269.
9. Ward CJ, Yuan D, Masyuk TV et al. Cellular and subcellular localization of
the ARPKD protein; fibrocystin is expressed on primary cilia. Hum Mol
Genet 2003; 12: 2703–2710.
10. Bergmann C, Senderek J, Sedlacek B et al. Spectrum of mutations in gene
for autosomal recessive polycystic kidney disease (ARPKD/PKHD1). J Am
Soc Nephrol 2003; 14: 76–89.
11. Wang S, Luo Y, Wilson PD et al. The autosomal recessive polycystic kidney
disease protein is localized to primary cilia, with concentration in the
basal body area. J Am Soc Nephrol 2004; 15: 592–602.
12. Zhang MZ, Mai W, Li C et al. PKHD1 protein encoded by the gene for
autosomal recessive polycystic kidney disease associates with basal
bodies and primary cilia in renal epithelial cells. Proc Natl Acad Sci USA
2004; 101: 2311–2316.
13. Wilson PD. Polycystic kidney disease. N Engl J Med 2004; 350: 151–164.
14. Torres VE, Harris PC. Mechanisms of disease: autosomal dominant
and recessive polycystic kidney diseases. Nat Clin Pract Nephrol 2006; 2:
40–55.
15. Bergmann C, Senderek J, Kupper F et al. PKHD1 mutations in autosomal
recessive polycystic kidney disease (ARPKD). Hum Mutat 2004; 23:
453–463.
16. Bergmann C, Senderek J, Schneider F et al. PKHD1 mutations in families
requesting prenatal diagnosis for autosomal recessive polycystic kidney
disease (ARPKD). Hum Mutat 2004; 23: 487–495.
17. Bergmann C, Senderek J, Windelen E et al. Clinical consequences of
PKHD1 mutations in 164 patients with autosomal-recessive polycystic
kidney disease (ARPKD). Kidney Int 2005; 67: 829–848.
18. Sharp AM, Messiaen LM, Page G et al. Comprehensive genomic
analysis of PKHD1 mutations in ARPKD cohorts. J Med Genet 2005; 42:
336–349.
19. Losekoot M, Haarloo C, Ruivenkamp C et al. Analysis of missense variants
in the PKHD1-gene in patients with autosomal recessive polycystic kidney
disease (ARPKD). Hum Genet 2005; 118: 185–206.
20. Adeva M, El-Youssef M, Rossetti S et al. Clinical and molecular
characterization defines a broadened spectrum of autosomal
recessive polycystic kidney disease (ARPKD). Medecine (Baltimore)
2006; 85: 1–21.
21. Furu L, Onuchic LF, Gharavi A et al. Milder presentation of recessive
polycystic kidney disease requires presence of amino acid substitution
mutations. J Am Soc Nephrol 2003; 14: 2004–2014.
22. Bergmann C, Kupper F, Dornia C et al. Algorithm for efficient PKHD1
mutation screening in autosomal recessive polycystic kidney disease
(ARPKD). Hum Mutat 2005; 25: 225–231.
23. Osathanondh V, Potter EL. Pathogenesis of polycystic kidneys. Type 1 due
to hyperplasia of interstitial portions of collecting tubules. Arch Pathol
1964; 77: 466–473.
24. Nakanishi K, Sweeney Jr WE, Zerres K et al. Proximal tubular cysts in fetal
human autosomal recessive polycystic kidney disease. J Am Soc Nephrol
2000; 11: 760–763.
25. Avner ED, Studnicki FE, Young MC et al. Congenital murine polycystic
kidney disease. I. The ontogeny of tubular cyst formation. Pediatr Nephrol
1987; 1: 587–596.
26. Nauta J, Ozawa Y, Sweeney Jr WE et al. Renal and biliary abnormalities in
a new murine model of autosomal recessive polycystic kidney disease.
Pediatr Nephrol 1993; 7: 163–172.
27. Moyer JH, Lee-Tischler MJ, Kwon HY et al. Candidate gene associated with
a mutation causing recessive polycystic kidney disease in mice. Science
1994; 264: 1329–1333.
28. Ricker JL, Gattone 2nd VH, Calvet JP et al. Development of autosomal
recessive polycystic kidney disease in BALB/c-cpk/cpk mice. J Am Soc
Nephrol 2000; 11: 1837–1847.
29. Woollard JR, Punyashtiti R, Richardson S et al. A mouse model of
autosomal recessive polycystic kidney disease with biliary duct and
proximal tubule dilatation. Kidney Int 2007; 72: 328–336.
Kidney International (2010) 77, 350–358 357
E Denamur et al.: Renal/hepatic histology and PKHD1 mutations o r ig ina l a r t i c l e
30. Nagasawa Y, Matthiesen S, Onuchic LF et al. Identification and
characterization of Pkhd1, the mouse orthologue of the human ARPKD
gene. J Am Soc Nephrol 2002; 13: 2246–2258.
31. Lo HS, Wang Z, Hu Y et al. Allelic variation in gene expression is common
in the human genome. Genome Res 2003; 13: 1855–1862.
32. Rossetti S, Harris PC. Genotype-phenotype correlations in autosomal
dominant and autosomal recessive polycystic kidney disease. J Am Soc
Nephrol 2007; 18: 1374–1380.
33. Hiesberger T, Shao X, Gourley E et al. Role of the hepatocyte nuclear
factor-1beta (HNF-1beta) C-terminal domain in Pkhd1 (ARPKD)
gene transcription and renal cystogenesis. J Biol Chem 2005; 280:
10578–10586.
34. Mrug M, Li R, Cui X et al. Kinesin family member 12 is a candidate
polycystic kidney disease modifier in the cpk mouse. J Am Soc Nephrol
2005; 16: 905–916.
35. Garcia-Gonzalez MA, Menezes LF, Piontek KB et al. Genetic
interaction studies link autosomal dominant and recessive polycystic
kidney disease in a common pathway. Hum Mol Genet 2007; 16:
1940–1950.
36. Kim I, Fu Y, Hui K et al. Fibrocystin/polyductin modulates renal tubular
formation by regulating polycystin-2 expression and function. J Am Soc
Nephrol 2008; 19: 455–468.
37. Kim I, Li C, Liang D et al. Polycystin-2 expression is regulated by a
PC2-binding domain of intracellular portion of fibrocystin. J Biol Chem
2008; 283: 31559–31566.
38. Kissane JM. Renal cysts in pediatric patients. A classification and
overview. Pediatr Nephrol 1990; 4: 69–77.
39. Mac Rae Dell K, Mc Donald RA, Watkins SL et al. Polycystic Kidney
disease. In: Avner ED, Harmon WE, Niaudet P (eds). Pediatric Nephrology,
Lippincott Williams and Wilkins: Philadelphia, USA. 5th edn 2004
pp 675–699.
40. Gagnadoux MF. Cystic diseases. In: Davison AM, Cameron JS, Grunfeld JP
et al. (eds). Oxford Textbook of Clinical Nephrology, Oxford University
Press: New York, USA. 3rd edn 2005 pp 2297–2304.
358 Kidney International (2010) 77, 350–358
or ig ina l a r t i c l e E Denamur et al.: Renal/hepatic histology and PKHD1 mutations
